Ondansetron for the Treatment of Methamphetamine Dependence - 1

National Institutes of Health (NIH)

Status and phase: Completed; Phase 2

Conditions: Amphetamine-Related Disorders

Treatments: Drug: Ondansetron

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00040053

NIDA-CTO-0011-1

Details and patient eligibility

About

The purpose of this study is to assess ondansetron for the treatment of methamphetamine dependence.

Full description

This study was designed to be a preliminary assessment of the efficacy and safety of 3-wide range doses of ondansetron (0.25, 1.0 and 4.0 mg taken orally twice per day) to reduce methamphetamine use in subjects with methamphetamine dependence and to determine the optimal dose of ondansetron.

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

18 years of age. Treatment seeking for meth dependence.

Exclusion criteria

Please contact site director for more details.